Notable Labs

Notable Labs Revenue per Employee

The Revenue per Employee of Notable Labs (NTBLQ) as of Nov 8, 2026 is 44,285.71 USD. In the previous year, Revenue per Employee was 94,285.71 USD — a change of -53.03% (lower).

Revenue per Employee

44,285.71USD

YoY

-53.03%

Last updated:

Revenue per Employee of Notable Labs is 2023 44,285.71 USD. Revenue per Employee of Notable Labs was 2022 94,285.71 USD. It decreases by -53.03% lower compared to the previous year.

The Notable Labs Revenue per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Employee
Date
Revenue per Employee
Jan 1, 2017
1.98 M USD
Jan 1, 2018
84,285.71 USD
Jan 1, 2019
80,000.00 USD
Jan 1, 2020
131,428.57 USD
Jan 1, 2021
110,000.00 USD
Jan 1, 2022
94,285.71 USD
Jan 1, 2023
44,285.71 USD
The Notable Labs Revenue per Employee history
YEARRevenue per EmployeeYoY
44,285.71USD-53.03%
94,285.71USD-14.29%
110,000.00USD-16.30%
131,428.57USD+64.29%
80,000.00USD-5.08%
84,285.71USD-95.74%
1.98 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Revenue per Employee of Notable Labs is 44,285.71 USD in 2023.

Revenue per Employee of Notable Labs changed from 94,285.71 USD to 44,285.71 USD, representing a -53.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Employee Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Revenue per employee measures workforce productivity by dividing total revenue by the number of employees. Higher values indicate more efficient operations.

Revenue per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Revenue per Employee's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Notable Labs

All Key Metrics — Notable Labs